All In Biotech

NDA 018998 · Bausch

Vasotec

Enalapril Maleate · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Aug 1, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1985

Dec 24, 1985

Approved uses

6

Original approval plus efficacy supplements

Registered trials

156

43 Phase 3, 13 recruiting

FAERS reports

24,669

19,955 serious, 2,779 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. • When pregnancy is detected, discontinue VASOTEC ® as soon as possible. • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (see WARNINGS, Fetal Toxicity ).

What it is approved for

From the label in effect Jan 23, 2026.

INDICATIONS AND USAGE Hypertension VASOTEC is indicated for the treatment of hypertension. VASOTEC is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of VASOTEC and thiazides are approximately additive. Heart Failure VASOTEC is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients VASOTEC improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY , Heart Failure , Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), VASOTEC decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY , Heart Failure , Mortality Trials for details and limitations of survival trials). In using VASOTEC consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that VASOTEC does not have a similar risk (see WARNINGS , Neutropenia/Agranulocytosis ). In considering use of VASOTEC, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS , Head and...

Mechanism: Mechanism of Action Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of enalapril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 13, 2001 Supplement 59 · Efficacy ReviewLetterLabel
  • Nov 4, 1993 Supplement 32 · Efficacy
  • Apr 8, 1992 Supplement 27 · Efficacy
  • Jun 12, 1990 Supplement 22 · Efficacy Review
  • Jun 24, 1988 Supplement 7 · Efficacy
  • Dec 24, 1985 Original approval · Type 1 - New Molecular Entity · priority review Other Important Information from FDAReview
4 products under this application
  • VASOTEC · ENALAPRIL MALEATE 2.5MG · TABLET, ORAL · Prescription · TE AB
  • VASOTEC · ENALAPRIL MALEATE 20MG · TABLET, ORAL · Prescription · TE AB
  • VASOTEC · ENALAPRIL MALEATE 5MG · TABLET, ORAL · Prescription · TE AB
  • VASOTEC · ENALAPRIL MALEATE 10MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Enalapril" as an intervention, any sponsor and status, largest first.

All 156 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea1,385
  • dyspnoea1,286
  • diarrhoea1,275
  • fatigue1,141
  • dizziness1,107
  • drug ineffective1,010
  • pain954
  • vomiting929
  • asthenia897
  • hypertension889
  • headache877
  • drug interaction848

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,375
20051,306
20061,534
20071,346
20081,745
20091,585
20101,975
20112,502
20122,006
2013564
20141,001
2015785
2016786
2017785
2018815
2019761
2020643
2021625
2022604
2023585
2024564
2025447
2026327

Recalls

1 FDA enforcement reports for this application.

  • May 21, 2014 · Class III · Terminated

    Labeling: Incorrect or Missing Package Insert: Product is packaged with the incorrect version of the package insert.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vasotec (Enalapril Maleate)

2024 spending

$3.3M

Beneficiaries

265

1,253 claims

Per beneficiary

$12,335

$24.97 per unit

View as table
YearSpending
2020$4,856,329
2021$4,109,497
2022$3,579,427
2023$3,361,199
2024$3,268,686

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,933 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.